July 2024
Sanofi’s Dupixent Sales Surpass €3 Billion for the First Time
Sanofi, Dupixent, quarterly sales, record high, asthma medicine, earnings forecast
Samsung Bioepis Sees 107% Sales Growth in Q2, Driven by Biosimilars
Samsung Bioepis, biosimilars, sales growth, Q2, operating profit, market share
Pfizer and Sangamo’s Gene Therapy Shows Superiority Over Prophylaxis in Hemophilia A Study
Pfizer, Sangamo, gene therapy, hemophilia A, prophylaxis, giroctocogene fitelparvovec, bleeding rate, Factor VIII
Autobahn Therapeutics Advances to Phase II for Mood Disorders with $100M Financing
Autobahn Therapeutics, Phase II, Mood Disorders, Financing, Pharmaceutical Industry
AstraZeneca Acquires Pinetree’s EGFR Degrader for $45 Million Upfront
AstraZeneca, Pinetree Therapeutics, EGFR degrader, protein degrader, oncology, licensing agreement, milestone payments, royalties, targeted protein degradation, molecular glues, cancer treatment
PBM Executives Avoid Tough Questions in House Committee Hearing
PBM executives, House committee hearing, pharmacy benefit managers, CVS Caremark, Express Scripts, Optum Rx
FDA Requests Additional Study on AstraZeneca’s Imfinzi for Lung Cancer Treatment
FDA, AstraZeneca, Imfinzi, Lung Cancer, Surgery, Adcomm
FDA Issues Warning Letter to Indian CDMO Brassica for Data Falsification and Poor Hygiene Practices
FDA, Warning Letter, Brassica Pharma, Data Falsification, Poor Hygiene, Indian CDMO, CGMP Violations
Geron Corporation Loses Chief Commercial Officer Following FDA Approval of RYTELO
Geron Corporation, Chief Commercial Officer, FDA Approval, RYTELO, Blood Cancer Treatment
Novo Nordisk’s Wegovy Receives UK Approval to Reduce Cardiovascular Risks in Overweight and Obese Adults
Wegovy, Novo Nordisk, UK approval, cardiovascular risks, weight loss, obesity, GLP-1 receptor agonist, semaglutide